Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF

Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF

315402

Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF

Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce the risk of death in idiopathic pulmonary fibrosis (IPF), the most common form of pulmonary fibrosis, the researchers said. The scientists wrote that “similar efficacy [was] shown…

You must be logged in to read/download the full post.